Interest of selective progesterone receptor modulators in endometriosis;Intérêt actuel des selective progesterone receptor modulators (SPRM) dans l'endomé triose

Gynecologie Obstetrique et Fertilite

Volumn 41, Issue 9, 2013, Pages 524-528

  Merviel, P ^a   Lourdel, E ^a   Sanguin, S ^a   Gagneur, O ^a   Cabry, R ^a   Nasreddine, A ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Endometriosis; Endometrium; Pelvic pain; SPRM; Ulipristal acetate

Indexed keywords

PROGESTERONE RECEPTOR MODULATOR; PROSTAGLANDIN;

AMENORRHEA; ANOVULATION; ARTICLE; ENDOMETRIOSIS;

DOULEUR PELVIENNE; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMÈTRE; ENDOMÉTRIOSE; PELVIC PAIN; SPRM; ULIPRISTAL ACETATE;

AMENORRHEA; ANIMALS; ANOVULATION; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HORMONE ANTAGONISTS; HUMANS; NORETHINDRONE; NORPREGNADIENES; PROGESTERONE; PROSTAGLANDINS; RECEPTORS, PROGESTERONE;

EID: 84888389991     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2013.07.016     Document Type: Article

References (25)

1. Spitz IM. Progesterone antagonists and progesterone receptor modulators: An overview. Steroids 2003;68:981-93.
2. Philibert D, Devraedt R, Teutsch G.In: RU 38486: A potent antiglucocorticoid in vivo; 1981.
3. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifep-ristone on breast cell prolifertaion in premenopausal women evaluated through tine needle aspiration cytology. Hum Reprod 2008;23:2072-9.
4. O'Malley BW. Coregulators: from when came these master genes". Mol Endocrinol 2007;21:1009-13.
5. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20.
6. Catherino WH, Parrott E, Segars J. Proceedings from the National Institute of Child Health and Human Development conference on the Uterine Fibroids Research Update Workshop. Fertil Steril 2011;95:9-12.
7. Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32.
8. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of BRCA1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70.
9. Brosens IA. Endometriosis - A disease because it is characterized by bleeding. Am J Obstet Gynecol 1997;176:263-7.
10. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345:266-75.
11. Farquhar C, Sutton C. The evidence for the management of endometriosis. Curr Opin Obstet Gynecol 1998;10:321-32.
12. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-6.
13. Chishima F, Hayakawa S, Sugita K, Kunikawa N, Aleemuzzaman S, Nemoto N, et al. Increased expression of cyclooxygenase-2 in local lesions of endometri-osis patients. Am J Reprod Immunol 2002;48:50-6.
14. Giudice LC. Genomics' role in understanding the pathogenesis of endometri-osis. Semin Reprod Med 2003;21:119-24.
15. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonado- Tropin-relaesing hormone agonist for endometriosis treatment and bone maintenance: A 1-year primate study. J Clin Endocrinol Metab 1996; 81:1933-9.
16. Stoeckemann K, Hegele-Hartung C, Chwalisz K. Effects of the progesterone antagonists onapristone (ZK 98299) and ZK 136799 on surgically induced endometriosis in intact rats. Hum Reprod 1995;10:3264-71.
17. Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharmac Sci 2010;39:421-7.
18. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6.
19. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38.
20. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progester-one receptor modulators with respect to PR-agonistic and antagonistic activi-ty. Steroids 2000;65:713-23.
21. Huniadi CA, Pop OL, Antal TA, Stamatian F. The effects of ulipristal on Bax/Bcl- 2, cytochrome C, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis. Eur J Obstet Gynecol Reprod Biol 2013. http://dx.doi.org/10.1016/j.ejorb [in press].
22. Jones RK, Searle RF, Stewart JA, Turner S, Bulmer JN. Apoptosis, bcl-2 expression, and proliferation human activity in human endometrial stroma and endometrial granulated lymphocytes. Biol Reprod 1998;58:995-1002.
23. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6: 513-9.
24. Brenner RM, Slayden OD, Nath A, Tsong YY, Sitruk-Ware R. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2009;81:336-42.
25. Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathol 2008;21:591-8.